Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa.
Retina. 2020 Nov;40(11):2221-2225. doi: 10.1097/IAE.0000000000002824.
To describe the retention of large, tubular, nondissolving foreign bodies because of a complication of the intravitreal dexamethasone implant (Ozurdex).
This is a single-center, retrospective chart review of patients who were found to have retained, nondissolvable tubular foreign bodies in the vitreous cavity for more than 6 months (the expected dissolution time of the implants) after Ozurdex injections. Ocular symptomatology and multimodal imaging were reviewed.
Five patients had retained, nondissolvable tubular foreign bodies in the vitreous that persisted for months (mean 28.2 months, range 9-67 months) after intravitreal injection of Ozurdex. Two patients were symptomatic due to the foreign bodies and chose alternate local therapy, but none of the patients opted for surgical explantation.
Persistent, nondissolving, tubular foreign bodies can be seen in the vitreous cavity for years after injection of the Ozurdex implant. Clinicians should be aware of this complication that has the potential to cause visual symptoms and ocular morbidity.
描述由于玻璃体内地塞米松植入物（Ozurdex）的并发症而导致的大管状不溶解异物的保留。
这是一项单中心、回顾性图表研究，纳入了在Ozurdex 注射后超过 6 个月（植入物预期溶解时间）仍在玻璃体内发现保留的、不溶解的管状异物的患者。回顾了眼部症状和多模态成像。
5 名患者在玻璃体内有保留的、不溶解的管状异物，在玻璃体内注射 Ozurdex 后持续数月（平均 28.2 个月，范围 9-67 个月）。由于异物，2 名患者出现症状并选择了替代局部治疗，但没有患者选择手术取出。
Ozurdex 植入物注射后多年，玻璃体腔内仍可出现持续存在的、不溶解的管状异物。临床医生应意识到这种可能导致视觉症状和眼疾的并发症。
